Axillary dissection: An obsolete operation?

Breast Journal

Volumn 4, Issue 5, 1998, Pages 330-335

  Morrow, Monica ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Axillary dissection; Breast cancer; Morbidity; Patient selection

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER SIZE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MASTECTOMY; MUSCLE WEAKNESS; PARESTHESIA; PATIENT SELECTION;

EID: 0031728472     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.450330.x     Document Type: Article

References (41)

1. Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66: 136-38.
2. Linn PP, Allison DC, Wainstock J, et al Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-44.
3. Hladiuk M, Huchcroft S, Temple W, Schnurr BE. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992;50:47-52.
4. Werner RS, McCormick B, Petrek J, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991;180:177-84.
5. Wilson RE, Donegan WL, Mettlin C, et al. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet 1984;159:309-18.
6. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-87.
7. Winchester DJ, Menck HR, Fregmen AM, Winchester DP. Selection criteria for axillary dissection in breast cancer. Presented at the 48th Cancer Symposium of the Society for Surgical Oncology, Houston, TX, March 1994.
8. Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinomas. Is it indicated? Cancer 1994;73:664-67.
9. McGee JM, Youmans R, Clingan F, et al. The value of axillary dissection in T1a breast cancer. Am J Surg 1996;172: 501-5.
10. Silverstein MJ, Waisman JR, Gierson ED, et al. Can axillary lymph node dissection be eliminated for selected patients with invasive breast cancer by using a combination of tumor size and palpability to predict nodal positivity? Proc Am Soc Clin Oncol 1994;13:56.
11. . Walls J, Boggis CR, Wilson M, et al. Treatment of the axilla in patients with screen-detected breast cancer. Br J Surg 1993;80:436-38.
12. Harris JR, Morrow M. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996:487-547.
13. Wilhelm MC, Edge SB, Cole D, et al. Nonpalpable invasive breast cancer. Ann Surg 1992;213:600-605.
14. Seidman JD, Schnaper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastases. Cancer 1995;75:65-71.
15. American Joint Committee on Cancer. Breast. In: Beahrs OH, Henderson DE, Hutter RVP, et al., eds. Manual for Staging of Cancer, 4th ed. Philadelphia: J.B. Lippincott, 1992:149.
16. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997;79:1918-22.
17. Ravdin P, DeLaurentis M, Wenger C, et al. Can prognostic factors be used to predict the nodal status of breast cancer patients? Proc Am Soc Clin Oncol 1994;13:56.
18. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer 1977;39: 435-39.
19. Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-47.
20. Winchester DP, Menck HR, Osteen RT, Kraybill W. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995;2:207-13.
21. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990;66:102-8.
22. Solin LJ, Fowble BL, Schultz DJ, et al. Definitive irradiation for intraductal carcinoma of the breast. Int J Radiol Oncol Biol 1990;19:843-50.
23. Baker LH. Breast Cancer Detection Demonstration Project. Five-year summary report. CA Cancer J Clin 1982;32: 194-225.
24. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298-302.
25. Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiol Oncol Biol Phys 1992;23:961-68.
26. . Frazier TG, Copeland EM, Gallagher HS, et al. Prognosis and treatment in minimal breast cancer. Am J Surg 1997; 133:697-701.
27. Nevin JE, Pinzon G, Moran TJ, Beggerly JT. Minimal breast cancer. Am J Surg 1980;139:357-59.
28. Schuh ME, Nemoto T, Penetrante RB, et al. Intraductal carcinoma. Analysis of presentation, pathologic findings and outcome of disease. Arch Surg 1986;121:1303-7.
29. Kinne DW, Petrek JA, Osborne MP, et al. Breast carcinoma in situ. Arch Surg 1989;124:33-36.
30. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982;6:401-11.
31. Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast. Clinical pathologic correlations based on 100 cases. Ann Surg 1981;193:138-49.
32. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15.
33. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 1992;84:1479-85.
34. Berlanger D, Moore M, Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol 1991;9:7-16.
35. Early stage breast cancer. Consensus Statement 1990; 8:1-19.
36. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
37. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
38. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
39. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
40. Trojani M, deMascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of the breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
41. Pickren JW. Significance of occult metastases. Cancer 1961;14:1266-71.